HUP0101012A2 - Orálisan adagolható gyógyszerkompozíció - Google Patents

Orálisan adagolható gyógyszerkompozíció

Info

Publication number
HUP0101012A2
HUP0101012A2 HU0101012A HUP0101012A HUP0101012A2 HU P0101012 A2 HUP0101012 A2 HU P0101012A2 HU 0101012 A HU0101012 A HU 0101012A HU P0101012 A HUP0101012 A HU P0101012A HU P0101012 A2 HUP0101012 A2 HU P0101012A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
oral administration
effect
tetrahydropyridine
trifluoromethylfend
Prior art date
Application number
HU0101012A
Other languages
English (en)
Inventor
Claude Aleman
Philippe Bastard
Marielle Bonnel
Thierry Breul
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of HUP0101012A2 publication Critical patent/HUP0101012A2/hu
Publication of HUP0101012A3 publication Critical patent/HUP0101012A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

Találmányunk tárgya iható vizes oldat, amely 1-[2-(2-naftil)-etil]-4-(3-trifluormetil-fend)-1,2,3,6-tetrahidropiridin-hidrokloridot <-ciklodextrint (<-CD), és valamely gyógyászatilag elfogadott savat vagypuffert tartalmaz, amely 3 vagy ennél alacsonyabb pH-t biztosít. Afenti tetrahidropiridinszármazéknak ismert az antidepresszív hatása,az idegszövetet tápláló hatása, székrekedés ellenes hatása. Ó
HU0101012A 1997-12-24 1998-12-14 Pharmaceutical composition for oral administration HUP0101012A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9716529A FR2772614B1 (fr) 1997-12-24 1997-12-24 Solution aqueuse a base de chlorhydrate de 1- [ 2-(2-naphtyl)ethyl]-4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine et composition pharmaceutique buvable en contenant
PCT/FR1998/002712 WO1999033466A1 (fr) 1997-12-24 1998-12-14 Composition pharmaceutique buvable

Publications (2)

Publication Number Publication Date
HUP0101012A2 true HUP0101012A2 (hu) 2001-08-28
HUP0101012A3 HUP0101012A3 (en) 2002-12-28

Family

ID=9515152

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101012A HUP0101012A3 (en) 1997-12-24 1998-12-14 Pharmaceutical composition for oral administration

Country Status (25)

Country Link
US (1) US6191137B1 (hu)
EP (1) EP1041984B1 (hu)
JP (1) JP2002510599A (hu)
AR (1) AR017722A1 (hu)
AT (1) ATE252384T1 (hu)
AU (1) AU1880599A (hu)
BR (1) BR9814414A (hu)
CA (1) CA2315696C (hu)
CO (1) CO4970813A1 (hu)
DE (1) DE69819203T2 (hu)
DK (1) DK1041984T3 (hu)
DZ (1) DZ2676A1 (hu)
ES (1) ES2209238T3 (hu)
FR (1) FR2772614B1 (hu)
GT (1) GT199800204A (hu)
HU (1) HUP0101012A3 (hu)
MY (1) MY117156A (hu)
NO (1) NO20003284L (hu)
PT (1) PT1041984E (hu)
SA (2) SA99191002B1 (hu)
SI (1) SI1041984T1 (hu)
TW (1) TW536409B (hu)
UY (1) UY25320A1 (hu)
WO (1) WO1999033466A1 (hu)
ZA (1) ZA9811824B (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087870A2 (en) * 2003-03-25 2004-10-14 The Johns Hopkins University Neuronal cell lineages and methods of production thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.

Also Published As

Publication number Publication date
CA2315696C (en) 2008-01-29
FR2772614A1 (fr) 1999-06-25
GT199800204A (es) 2000-06-14
AU1880599A (en) 1999-07-19
HUP0101012A3 (en) 2002-12-28
FR2772614B1 (fr) 2000-03-10
US6191137B1 (en) 2001-02-20
PT1041984E (pt) 2004-02-27
DE69819203T2 (de) 2004-07-15
EP1041984B1 (fr) 2003-10-22
CA2315696A1 (en) 1999-07-08
WO1999033466A1 (fr) 1999-07-08
NO20003284D0 (no) 2000-06-22
SA99191002B1 (ar) 2006-03-07
JP2002510599A (ja) 2002-04-09
ZA9811824B (en) 1999-06-29
TW536409B (en) 2003-06-11
MY117156A (en) 2004-05-31
DZ2676A1 (fr) 2004-09-19
SI1041984T1 (en) 2004-04-30
EP1041984A1 (fr) 2000-10-11
SA99191003B1 (ar) 2006-10-02
BR9814414A (pt) 2000-10-10
NO20003284L (no) 2000-08-24
DE69819203D1 (de) 2003-11-27
AR017722A1 (es) 2001-09-12
ES2209238T3 (es) 2004-06-16
DK1041984T3 (da) 2004-02-16
UY25320A1 (es) 2000-10-31
ATE252384T1 (de) 2003-11-15
CO4970813A1 (es) 2000-11-07

Similar Documents

Publication Publication Date Title
ES2157881T3 (es) Metanosulfonato de paroxetina.
HUP9603237A2 (hu) (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0101411A2 (hu) 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása
MX9505065A (es) Composicion farmaceutica, aplicable oralmente.
MX9505064A (es) Composicion farmaceutica, aplicable oralmente.
BG105257A (en) New oral formulation for 5-ht4 agonists or antagonists
IL124091A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it&#39;s preparation,use of the compound and pharmaceutical compositions containing the same
DE69721838D1 (de) 1-[1-(4-chlorphenyl)cyclobutyl]-3-methylbutyl amin derivate zur senkung von harnsäurespiegeln beim menschen
HUP0401484A2 (hu) BIBN4096 alkalmazása kombinációban más migrénellenes szerekkel migrén kezelésére és a kombinációt tartalmazó gyógyszerkészítmények
UA41978C2 (uk) N-метил-n-[(1s)-1-феніл-2-((3s)-3-гідроксипіролідин-1-іл)етил]-2,2- дифенілацетамід гідрохлорид, спосіб його отримання та фармацевтична композиція
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
HUP0101012A2 (hu) Orálisan adagolható gyógyszerkompozíció
HUP0004900A2 (hu) Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények
BG105434A (en) Sertraline oral concentrate
HUP0400889A3 (en) Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound
NZ508325A (en) Microemulsion preconcentrates for oral administration containing a piperidine substance P antagonist
HU9600758D0 (en) Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
GEP20043377B (en) Pharmaceutical Complex
AP9801417A0 (en) Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders.
HUP0001181A2 (hu) Mikrorészecske formájú tetrahidropiridinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények
DE69730515D1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen
HUP0202972A2 (hu) Vazopresszin antagonista készítmény és eljárás az előállítására
HUP0204297A2 (hu) (-)-cisz-2-(2-Klór-fenil)-5,7-dihidroxi-8-[4R-(3S-hidroxi-1-metil)-piperidinil]-4H-1-benzopirán-4-on etanolos szolvátja, eljárás az előállítására és ezeket tartalmazó gyógyszerkészítmények
UY24823A1 (es) Procedimiento para la preparacion de un derivado de tetrahidropiridina.

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished